Investors Purchase High Volume of Call Options on Aurora Cannabis (NASDAQ:ACB)

Aurora Cannabis Inc. (NASDAQ:ACB) was the recipient of unusually large options trading activity on Monday. Investors bought 2,710 call options on the company. This represents an increase of approximately 248% compared to the typical volume of 778 call options.

Institutional Investors Weigh In On Aurora Cannabis

A number of large investors have recently bought and sold shares of the business. Tidal Investments LLC increased its holdings in Aurora Cannabis by 1.2% during the 2nd quarter. Tidal Investments LLC now owns 1,264,494 shares of the company’s stock valued at $3,528,000 after purchasing an additional 14,827 shares in the last quarter. Two Sigma Securities LLC acquired a new position in Aurora Cannabis in the second quarter worth $36,000. State of Wyoming bought a new stake in shares of Aurora Cannabis during the second quarter worth $56,000. Baader Bank Aktiengesellschaft increased its stake in shares of Aurora Cannabis by 37.3% in the first quarter. Baader Bank Aktiengesellschaft now owns 33,060 shares of the company’s stock valued at $108,000 after buying an additional 8,990 shares in the last quarter. Finally, Leonteq Securities AG raised its holdings in shares of Aurora Cannabis by 24.7% in the first quarter. Leonteq Securities AG now owns 42,839 shares of the company’s stock valued at $140,000 after buying an additional 8,472 shares during the last quarter. 47.63% of the stock is currently owned by institutional investors.

Aurora Cannabis Trading Up 13.8%

Shares of ACB stock opened at $4.46 on Tuesday. Aurora Cannabis has a 12-month low of $2.56 and a 12-month high of $6.66. The company has a market capitalization of $293.13 million, a P/E ratio of -3.16 and a beta of 0.63. The firm has a 50-day moving average price of $3.71 and a 200 day moving average price of $3.38. The company has a quick ratio of 2.80, a current ratio of 5.36 and a debt-to-equity ratio of 0.03.

Aurora Cannabis (NASDAQ:ACB) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.17. The firm had revenue of $47.62 million for the quarter, compared to analysts’ expectations of $47.45 million. Aurora Cannabis had a negative net margin of 32.26% and a positive return on equity of 4.37%. Research analysts forecast that Aurora Cannabis will post -0.07 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Weiss Ratings upgraded Aurora Cannabis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. Wall Street Zen upgraded Aurora Cannabis from a “sell” rating to a “hold” rating in a research report on Sunday, September 13th. BMO Capital Markets raised Aurora Cannabis to a “hold” rating in a research note on Wednesday, August 5th. Finally, Zacks Research raised Aurora Cannabis from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy”.

About Aurora Cannabis

Aurora Cannabis Inc is a Canadian cannabis company focused primarily on the production, distribution and sale of medical cannabis. The company offers cannabis products such as dried flower, pre-rolls, oils, softgels, capsules and other formulations through its medical and consumer brands.

Founded in 2013 and headquartered in Edmonton, Alberta, Aurora serves adult-use and medical markets in Canada and supplies medical cannabis to selected international markets. Its international operations and partnerships have included markets in Europe, Australia and other regions where cannabis is permitted for medical use.

Aurora sells products under brands including Aurora, CanniMed, MedReleaf and San Rafael ’71.